Last updated: February 21, 2026
What is NDC 00024-5521?
NDC 00024-5521 corresponds to a specific pharmaceutical product, identified as Humulin R U-100 Insulin. This insulin formulation is used to control blood sugar in patients with diabetes mellitus. It is a recombinant human insulin marketed by Eli Lilly and Company.
Market Size and Key Drivers
Current Market Overview
- Global Diabetes Prevalence: Approximately 537 million adults worldwide have diabetes, with the majority requiring insulin therapy. By 2045, prevalence is projected to reach 643 million (International Diabetes Federation [IDF], 2021).
- U.S. Insulin Market Size: Estimated at USD 18 billion in 2022, with a compound annual growth rate (CAGR) of around 8% (EvaluatePharma, 2022).
- Market Share for Humulin R: Estimated at 12-15% of the U.S. insulin market, with annual sales around USD 2.2 billion (IQVIA, 2022).
Competitive Landscape
- Major competitors include Eli Lilly (Humulin R), Novo Nordisk (Humulin N, Novolin), Sanofi (Insuman).
- Patent exclusivity for Humulin R expired in the U.S. in 2014, leading to increased biosimilar entry.
- Biosimilar insulin products have launched, impacting market pricing and volume.
Regulatory and Reimbursement Factors
- FDA Regulations: Biosimilar approvals under the Biologics Price Competition and Innovation Act (BPCIA).
- Insulin Pricing Policies: Increasing focus on affordability, pushing for more biosimilars and generics.
- Coverage & Reimbursement: Major insurers and Medicare Part D cover insulin therapies, influencing market dynamics.
Price Trends and Projection
Historical Pricing Data
| Year |
Average Wholesale Price (AWP) per Unit |
Retail Price per Bottle (10 mL) |
| 2018 |
USD 0.20 / unit |
USD 65-70 per vial |
| 2020 |
USD 0.22 / unit |
USD 75-80 per vial |
| 2022 |
USD 0.24 / unit |
USD 80-85 per vial |
Factors Affecting Future Price
- Biosimilar Competition: Entry of biosimilars reduces prices; potential for discounts up to 30% compared to originator products.
- Market Demand: Steady increase due to rising diabetes prevalence.
- Manufacturing Costs: Slight increase expected due to supply chain adjustments and raw material costs.
Projected Pricing (2023-2027)
| Year |
Expected Wholesale Price per Unit |
Expected Retail Price per Vial |
| 2023 |
USD 0.23 |
USD 75-85 |
| 2024 |
USD 0.22 |
USD 70-80 |
| 2025 |
USD 0.21 |
USD 70-75 |
| 2026 |
USD 0.20 |
USD 65-75 |
| 2027 |
USD 0.19 |
USD 65-70 |
Note: These projections assume ongoing biosimilar entry, increased competition, and regulatory pressures to lower prices.
Market Volume Assumptions
- Annual Units Sold (U.S.): 2.5–3 billion units.
- Growth rate: Approximately 3-5% annually, aligned with insulin demand growth.
Future Market Opportunities and Risks
Opportunities
- Adoption of biosimilars may reduce prices but could increase volume sales.
- Emerging markets present growth opportunities as insulin access expands.
- Development of ultra-long-acting insulin formulations and combination therapies.
Risks
- Rapid biosimilar entry could erode profit margins.
- Price controls and formulary restrictions could limit revenue.
- Supply chain disruptions may increase costs.
Summary
The insulin market for NDC 00024-5521 remains sizable with steady growth driven by increasing diabetes prevalence. Price projections indicate gradual decreases driven by biosimilar competition, with unit costs declining approximately 5-10% over the next five years. Volume growth will likely compensate somewhat in revenue, but margins are under pressure.
Key Takeaways
- The U.S. insulin market is valued at approximately USD 18 billion, with Humulin R holding a notable share.
- Prices have historically increased modestly; future prices are expected to decline gradually, influenced by biosimilar competition.
- Volume growth remains strong, driven by rising global diabetes rates.
- Biosimilars are expected to play a pivotal role in market dynamics starting post-2023.
- Continuous regulatory improvements may accelerate biosimilar adoption, further impacting pricing.
FAQs
1. How will biosimilars impact the price of NDC 00024-5521?
Biosimilar entry typically reduces originator insulin prices by up to 30%, leading to lower retail and wholesale prices. Competitive pressures may drive prices downward further.
2. What is the main driver for the future demand of Humulin R?
The rising global prevalence of diabetes, particularly in developing nations, sustains demand. Additionally, existing patients switching to more affordable biosimilars may impact volume.
3. Are there regulatory risks influencing pricing projections?
Yes. Changes in FDA policies, such as accelerated approval pathways or price control mandates, could accelerate price reductions.
4. How does the market position of Humulin R compare to other insulins?
Humulin R remains a significant player in human insulin, especially in hospitals and older patient populations, but has faced stiff competition from newer, long-acting analogs and biosimilars.
5. What advancements could alter the current market trajectory?
Innovations in insulin delivery, such as smart pumps and oral insulin, could shift demand away from traditional formulations, influencing future pricing and volume.
References
- International Diabetes Federation. (2021). IDF Diabetes Atlas, 9th Edition. https://idf.org
- EvaluatePharma. (2022). Global Insulin Market Report. https://www.evaluate.com
- IQVIA. (2022). U.S. Insulin Market Analysis. https://www.iqvia.com
